Vincerx Pharma Inc
NASDAQ:VINC

Watchlist Manager
Vincerx Pharma Inc Logo
Vincerx Pharma Inc
NASDAQ:VINC
Watchlist
Price: 0.0502 USD -13.45% Market Closed
Market Cap: 262.5k USD

VINC's latest stock split occurred on Jan 28, 2025

The company executed a 1-for-20 stock split, meaning that for every 20 shares held, investors received 1 new share.

Before the split, VINC traded at 0.099 per share. Afterward, the share price was about 1.65.

The adjusted shares began trading on Jan 28, 2025. This was the only stock split in VINC's history.

Last Splits:
Jan 28, 2025
1-for-20
Pre-Split Price
1.98 0.099
Post-Split Price
1.65
Before
After
Last Splits:
Jan 28, 2025
1-for-20

Vincerx Pharma Inc
Stock Splits History

VINC Stock Splits Timeline
Jan 28, 2025
Jan 28, 2025
Split 1-for-20
/0.05
Pre-Split Price
1.98 0.099
Post-Split Price
1.65
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 22, 2025
Seres Therapeutics Inc
SWB:1S9
1-for-20
/20
0.3216 6.432 EUR 6.432 6.432 EUR
Apr 22, 2025
G
Golden Shield Resources Inc
F:4LE0
1-for-10
/10
0.011 0.11 EUR 0.11 0.11 EUR
Apr 22, 2025
E
EV Advanced Material Co Ltd
KOSDAQ:131400
911-for-787
x1.1575603557814
1493 1493 KRW 1439 1439 KRW
Apr 22, 2025
Seres Therapeutics Inc
F:1S9
1-for-20
/20
0.01 0.2 EUR 0.2 0.2 EUR
Apr 22, 2025
G
Golden Shield Resources Inc
OTC:GSRFF
1-for-10
/10
0.024 0.24 USD 0.24 0.24 USD
Load More

Vincerx Pharma Inc
Glance View

Market Cap
262.5k USD
Industry
Biotechnology

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. The company is headquartered in Palo Alto, California and currently employs 56 full-time employees. The company went IPO on 2020-03-10. The Company’s small molecule drug program includes VIP152, which is a highly selective, clinical-stage positive transcription elongation factor-beta/cyclin-dependent kinase 9 (PTEFb/CDK9) inhibitor. The firm's antibody-drug conjugate (ADC) platform includes VIP943 (targeting CD123) and VIP924 (targeting CXCR5), which are ADC compounds addressing known and novel oncology targets. The Company’s bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors.

VINC Intrinsic Value
Not Available
Back to Top